US FDA Commissioner Califf Takes On Misinformation, Starting With ‘Rumor Control’
Executive Summary
Agency leader expects to spend about a year developing a strategy to combat misinformation. On 5 August, the agency unveiled what appears to be an early component of the initiative – a web page titled Rumor Control, with facts about the safety and components of COVID-19 vaccines.
You may also be interested in...
Novavax Readying Multiple COVID-19 Vaccine Candidates To Ensure Fall Availability
CBER’s Marks said US FDA is working with Novavax on manufacturing to allow its protein-based vaccine to be ready for a fall roll-out. After some concerns about international coordination, multiple regulators seem to be settling on a monovalent approach for fall vaccinations.
US FDA Mulls Granting Regulated Industry Flexibility To Respond To Misinformation
The rapid pace with which inaccurate information can spread on social media may necessitate loosening some of FDA’s regulations on sponsors to let them respond, Commissioner Robert Califf said at the J.P. Morgan Healthcare Conference. Califf also worried about how legitimate debate can undermine public confidence in FDA.
US FDA Mulls Granting Regulated Industry Flexibility To Respond To Misinformation
The rapid pace inaccurate information spreads on social media may necessitate loosening some of FDA’s regulations to let sponsors respond, Commissioner Robert Califf said at J.P. Morgan Healthcare Conference. Califf also worried about how legitimate debate can undermine public confidence in FDA.